Evidence map›Paper›PMID 36675033›Full record

ReviewInternational journal of molecular sciences2023

Cannot Target What Cannot Be Seen: Molecular Imaging of Cancer Stem Cells.

Loredana G Marcu, Leyla Moghaddasi, Eva Bezak

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Cancer Stem Cells from Definition to Detection and Targeted Drugs.International journal of molecular sciences · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Loredana G MarcuFaculty of Informatics and Science, University of Oradea, 1 Universitatii Str., 410087 Oradea, Romania.ORCID 0000-0002-6703-979X
Leyla MoghaddasiNorthern Sydney Cancer Centre, Royal North Shore Hospital, St. Leonards, NSW 2065, Australia.
Eva BezakCancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0002-1315-1735

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells are known to play a key role in tumour development, proliferation, and metastases. Their unique properties confer resistance to therapy, often leading to treatment failure. It is believed that research into the identification, targeting, and eradication of these cells can revolutionise oncological treatment. Based on the principle that what cannot be seen, cannot be targeted, a primary step in cancer management is the identification of these cells. The current review aims to encompass the state-of-the-art functional imaging techniques that enable the identification of cancer stem cells via various pathways and mechanisms. The paper presents in vivo molecular techniques that are currently available or await clinical implementation. Challenges and future prospects are highlighted to open new research avenues in cancer stem cell imaging.

Indexed as

NeoplasmsPositron-Emission TomographyHumansMagnetic Resonance ImagingMolecular ImagingNeoplastic Stem CellsTomography, Emission-Computed, Single-Photonfunctional imagingmagnetic resonance imaging (MRI)personalised therapypositron emission tomography (PET)single photon emission tomography (SPECT)

Identifiers

PMID36675033
PMCPMC9864237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.